Search Results

<< Go back to the Podcast page EPISODE 3: SURGERY FOR NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE To cut or not to cut? A crossroad many neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope answers the top 10 surgery questions for NETs. MEET DR. GAGANDEEP SINGH Gagandeep Singh, M.D., is an internationally recognized liver and pancreas surgeon. He is head of hepatobiliary and pancreatic surgery service City of Hope, a National Cancer Institute-designated comprehensive cancer center. He is also the surgical director of the Neuroendocrine Tumor Program and is the lead for the gastrointestinal disease team. He started his faculty academic career at Keck School of Medicine of USC in Los Angeles. From there, he was appointed as director of the Liver and Pancreas Center at the John Wayne Cancer Institute, Santa Monica, California, where he also served as chair of the Cancer Committee and vice president for Fellowship Education. In 2010, City of Hope asked Dr. Singh to spearhead the liver and pancreatic cancer program. He was appointed clinical professor of surgery and as the new chief of the Division of Surgical Oncology (2011 to 2019) and hoisted the program to national recognition. He has an extensive referral base that reflects peer recognition of his clinical acumen and surgical expertise and is listed in “America’s Top Surgeons,” “Best Doctors of America,” “Super Doctors” and “Top Doctors of America.” Prior to his tenure in the Unites States, he earned is his medical degree from the Mahatma Gandhi Institute of Medical Sciences in India, and then trained at some of the finest cancer centers and hepatobiliary institutes around the world. These international institutions include: Tata Memorial Hospital and Cancer Center (Bombay, India), René Descartes University - Hôpital Cochin (Paris, France) and the Royal Liverpool University Hospital (England). In the U.S., these institutes include: Marion Bessin Liver Center at the Albert Einstein College of Medicine (New York), Maricopa Medical Center (Phoenix) and the University of Iowa Hospitals & Clinics (Iowa City). Dr. Singh is a board-certified surgeon, a diplomate of the American Board of Surgery and a fellow of the American College of Surgeons. He is a member of some of the top elite surgical societies and has served as invited speaker/chair at several national and international conferences. He is also a panel member of the National Comprehensive Cancer Network for Hepatobiliary Cancers, that lays down the guidelines for the standard of care for these cancers; providing direction to both patients and physicians across the U.S. and the rest of the world. Dr. Singh has a very thoughtful, effective and yet forceful approach to beating cancer, in a systematic fashion working with an outstanding multidisciplinary team. Dynamic and compassionate, he is a skilled and an accomplished surgeon. He has extensive experience in liver and pancreatic diseases and other gastrointestinal cancers. His work is very well published with numerous publications in prestigious journals. His publications encompass complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions following difficult pancreatic surgery for pancreatic cancer, and advanced robotic surgery. Currently, his group is advancing the scope and providing leading-edge surgery for complex liver and pancreatic operations using minimally invasive surgery techniques with the 3D high-definition da Vinci robotic surgical systems. His work in robotic surgery has been presented on the national podium at the Society of Surgical Oncology, Americas Hepato-Pancreato-Biliary Association, Society of Laparoscopic & Robotic Surgeons and other national meetings. An innovator at heart, Dr. Singh is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborative endeavors with engineers from California Institute of Technology (Caltech) & Harvey Mudd College. He has several invention disclosures and patents. In addition to a large clinical practice, Dr. Singh is passionately advancing leading-edge translational research. He collaborates with City of Hope’s molecular biologists, X-ray crystallographers, structural chemists and superresolution scientists. A visionary clinician, he is developing novel targeted molecules for neuroendocrine tumors, pancreatic cancers and metastatic colon and rectal cancers. He believes early detection is critical and is authenticating an early detection blood test for pancreatic cancers and colorectal cancers. ABOUT THIS EPISODE 1. Should all NET patients have surgery? How do I know if I’m a candidate for surgery? If 1 surgeon says I’m not, would another surgeon say something different? 2. How much control would a patient have regarding the approach and extent of surgery? 3. How do you control for carcinoid crisis during surgery? 4. Should all NET patients have their gallbladder removed? If mine wasn’t removed in my initial surgery, would you recommend going back to have it taken out? 5. If there are already liver mets, would you recommend having surgery? If so, how much should be taken out? Is there a role for taking out the primary tumor when there are liver mets? 6. Is there a role for surgery if there are bone mets? 7. What is the role of liver transplantation? 8. What are the risks of scar tissue from multiple surgeries? What can be done about it? (how many surgeries can a body handle?) 9. What is the role of adjuvant therapy for net? (Please also explain what adjuvant therapy is.) 10. What treatment or other development in this field are you most excited about? (What hope might you offer to those living with NET or their loved ones?) DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANKS TO OUR SPONSORS

Newly Diagnosed < Back to Topics Play Video Play Video 25:45 "NETS 101" • Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium @NCFCancer Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium • Santa Monica, CA Speaker: Jaydira Del Rivero, MD Medical Oncologist Endocrinologist National Cancer Institute, NIH For more information, visit LACNETS.org. Play Video Play Video 35:16 "Understanding NET Diagnosis" with Dr. Chandrasekharan • 2024 #LACNETS Patient Conference 2. "Understanding NET Diagnosis" with #Dr.Chandrasekharan Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. Play Video Play Video 21:51 NETS 101: Overview of NET Terms & Concepts • Dr. Aman Chauhan • 2023 LACNETS Patient Conference Watch "NETS 101: Overview of NET Terms & Concepts" with Dr. Aman Chauhan. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit, LACNETS.org. Play Video Play Video 15:22 05. NET Surgery: Making Decisions & Preparing for Surgery (Dr. Clarke) - 2022 LACNETS Conference Dr. Callisia Clarke addresses surgery for neuroendocrine cancer including decision-making & preparing for surgery. Presenter: Callisia Clarke, MD Surgical Oncologist Medical College of WI 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 07:50 Patient Story: NET Patient shares about the first year of her NET journey (LACNETS) NET Patient Laurie shares about the first year of her NET journey. November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 01:37:42 LACNETS Webinar: "Sequencing of Neuroendocrine Tumor Treatments" with Dr. Eric Liu LACNETS webinar - “Sequencing of Neuroendocrine Tumor Treatments" Friday, May 24th, 2020 SPEAKER: Dr. Eric Liu, General Surgeon & Neuroendocrine Specialist Rocky Mountain Cancer Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com Play Video Play Video 01:04:39 LACNETS - NET VITALS Webinar - September 6th, 2018 Download NET VITALS here: www.lacnets.org/netvitals NET VITALS Webinar - Question Timing Guide: Introductions: Start - 10:25 Q1. My neuroendocrine tumor (NET) was found: 10:41 Q2. I am a neuroendocrine tumor (NET) patient and my primary (origin) tumor is: 11:05 Q3. My NET has spread (metastasized) to: 11:57 Q4. My Ki-67 index is 14:20 Record-keeping: 14:38 Pathology report example: 17:25 Q5. My neuroendocrine tumor is: 18:15 Q6. My neuroendocrine tumor is: 22:17 Q7. I have symptoms: 23:50 Q8. I have had symptoms for ____ years (if applicable). 23:50 Q9. I have had the following types of imaging, and possess the disk and/or report: 29:30 Q10. I have had the following labs, and possess the report (if applicable): Indicate if abnormal. 32:55 Q11. Surgery to remove primary tumor(s): 38:45 Q12. Surgery to remove metastatic tumor(s): 39:05 Q13. Other surgery 39:40 Q14. Liver-Directed treatment: 40:10 Q15. Somatostatin Analogs (SSA) & Others: 42:48 Q16. Chemotherapy / Biologically-Targeted / Immunotherapy, including Clinical Trials/ PRRT (Peptide Receptor Radionuclide Therapy, i.e. Lutathera®): 44:03 Q17. I am diabetic: 47:50 Q18. ALLERGIES (Medications/Food): 48:05 Q19. FAMILY HISTORY (Specify cancer and/or rare diseases): 48:20 Q20. I have had Genetic Testing: 48:37 Q21. MEDICATIONS/SUPPLEMENTS (including vitamins, digestive enzymes): 49:01 Q22. CURRENT PHYSICIAN(S) & MEDICAL TEAM 49:29 Q23. SOCIAL SUPPORT 50:13 Q&A with the NET VITALS Team 52:23 What is NET Vitals? LACNETS created NET VITALS as a quick snapshot of the most important questions for patients and healthcare professionals to know about neuroendocrine cancer. NET VITALS is a 20-question tool designed to highlight the vitals of NET cancer, all in one document. This allows the physician and patient to more easily communicate with all of the basics in one place. Webinar Leaders: Giovanna Joyce Imbesi, MBA, Executive Director, LACNETS Lisa Yen, NP, NBC-HWC, Program Director, LACNETS Dan Li, MD, Medical Oncologist, City of Hope Josh Mailman, MBA, President, NorCal CarciNET Learn more here: https://www.lacnets.org/lacnets-blog/netvitals Play Video Play Video 20:22 "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (LACNETS) "Qué esperar de una consulta de expertos de NET" con Dr. Heloisa Soares (LACNETS) Presentadora: Heloisa Soares, MD, PhD Medical Oncologist; Huntsman Cancer Institute Para obtener más recursos en español, visite www.LACNETS.org. Play Video Play Video 30:23 04. What to Expect with a NET Expert Consultation (Dr. Soares) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Heloisa Soares, MD, PhD Medical Oncologist Huntsman Cancer Institute This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 42:50 Finding a NET Expert + Surgery for NETs - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: LACNETS Conference Welcome (0:00 - 5:44) Lindsey Jeu De Vine, Director of Communications, LACNETS Lisa Yen, NBC-HWC, Program Director, LACNETS "Finding a NET Expert" (5:44 - 22:25) Cindy Lovelace , Executive Director Healing NET Foundation "Surgery for NETs" (22:25 - end of video) Alexandra Gangi, MD , Surgical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 43:19 "NETs 101" with Medical Oncologist Dr. Sandy Kotiah of Mercy Medical Medical oncologist and NET expert Dr. Kotiah covers what to expect during your first visit with your medical oncologist – plus labs, scans, and prognosis. Speaker: Sandy D. Kotiah, MD Medical Oncologist, Hematologist Mercy Medical To learn more about LACNETS, visit www.LACNETS.org. < Back to Topics Next Topic >

NET Intro - Your NET Elevator Speech The NET Intro card can be filled out digitally using a PDF editor or printed and filled out. DOWNLOAD THE NET INTRO CARD Esta página también está disponible en español, se encuentra aquí. WHAT IS A NET ELEVATOR SPEECH? An elevator speech is a way of introducing yourself. The reason it’s called an “elevator speech” is because it should be short enough to say during a brief elevator ride. We define a NET elevator speech as a two-sentence synopsis of your NET cancer which can be communicated in 30 seconds or less. If you were in an elevator with a NET expert and had only 30 seconds, your NET elevator speech is your concise two-sentence introduction that relates the most important things they need to know about your disease. This is your NET Intro, the way you introduce yourself to someone who doesn’t yet know your NET history. Your NET elevator speech consists of two sentences, and contains items #2-6 on page 1 of NET VITALS . SENTENCE #1: 1. Your relationship to NET: If you are living with NET, you might start the sentence with: “I am living with…” “I was diagnosed with…” If you are an ally or loved one of someone living with NET, you might start the sentence with: “My spouse/child/parent/relative/friend/other relation is living with…” “My spouse/child/parent/relative/friend/other relation was diagnosed with…” Note: Because we believe words are powerful, we discourage identifying yourself as a patient or by the disease. Instead, we encourage using “I am living with” or “I was diagnosed with” or “I was diagnosed X year with…” or even “I have…” Some people even say “I am living well with…” because it gives the message that people can thrive while living with NETs. 2. Tumor differentiation: This is either "well differentiated" or "poorly differentiated.” It refers to how abnormal the cells look when compared to the surrounding healthy, non-cancer cells under the microscope. 3. Tumor grade: This is grade 1, 2, or 3. If you know your ki-67, you can add this element, as it determines the grade of the tumor. This refers to how quickly the tumor cells are dividing. It can be found on your pathology report, a report that is done whenever tissue is taken from your body, usually from a biopsy or surgery. Grade is different from stage which refers to how far the cancer has travelled from the original site of the tumor. It’s easy to confuse grade with stage, but they actually say very different things. The general public is familiar with staging, because it is a common way to describe a cancer and gives an idea of someone’s prognosis. However, it’s important to remember that stage 4 with neuroendocrine cancer does not mean the same thing as stage 4 with other cancers. Please note that lung NETs are not classified by grade; they are classified as typical carcinoma, atypical carcinoma, large cell neuroendocrine carcinoma, and small cell carcinoma. Pheochromocytomas and paragangliomas are also not classified by grade. NETWise Infographic Stage, Differentiation & Grade, courtesy of Neuroendocrine Tumor Research Foundation - Download Here Lung NET infographic, courtesy of Neuroendocrine Tumor Research Foundation - Download here Lung NET resources can be found here. 4. Functional status of the tumor: This is either functional or nonfunctional. This means specifically whether the tumors produce hormones (functional), or they do not produce hormones (nonfunctional). This is different from stating if you experience symptoms, since symptoms could be from a variety of reasons. This specifically refers to whether or not your tumors produce hormones that cause symptoms. 5. Site of tumor origin and metastases: This is where your tumor originates from (i.e. pancreas, small intestine, lung, colon, etc.) and anywhere else it might be located (i.e. liver, bones, etc.). The primary site of your tumor remains the same even after it has been removed and even if you no longer have evidence of disease. One reason the primary site of your tumor is important is that it helps your doctor determine what treatment options are available and best suited for you. 6. Year of diagnosis (optional) This is my example of sentence #1: "My husband has been living with well-differentiated, Grade 2 (ki-67 15) nonfunctional pancreatic NET with metastases to the liver and bones since 2015.” "My husband was diagnosed in 2015 with well-differentiated, Grade 2 (ki-67 15) nonfunctional pancreatic NET that has metastasized to the liver and bones.” SENTENCE #2: Sentence #1 is foundational. Once you’ve mastered sentence #1, then -- and only then-- are you ready to build on it by adding sentence #2. Most of us have an easier time with sentence #2 because we usually know what treatments we’ve had. Sentence #2 consists of a brief summary of your surgeries and treatments. The key here is to be succinct. This is my example of sentence #2: “My husband has had surgery, somatostatin analog (lanreotide or octreotide), liver directed therapy, and PRRT.” There it is—your NET story as a brief two-sentence NET Intro that takes less than 30 seconds. While it may sound simple, we recognize that building your elevator speech may not be easy. Furthermore, it takes work and practice to become comfortable delivering your elevator speech. Write it down. Have it handy. Then practice, practice, practice ! It takes repetition to become fluent in this new language so it rolls easily off the tongue. WHAT ARE THE BENEFITS OF LEARNING YOUR NET INTRO? You are learning to “speak NET” so you’re on the same page as a NET expert. By sharing your NET elevator speech, you are communicating the critical elements that they need to know to guide treatment decisions. It’s important that YOU know and understand your own disease, and don’t just rely on your medical team to do so. Learning to speak NET helps you know what information or treatments are relevant to you. When you participate in educational meetings, you might be better able to interpret and apply the information. When you look at clinical trials, you might be better able to understand whether you are a candidate for certain trials. It helps you communicate the essential elements of your neuroendocrine cancer concisely, clearly, and efficiently. Communicating the critical elements of the disease efficiently means that time can be better spent on other things such as talking about treatments or getting your questions answered. This might be in a support group setting or with others living with NETs. This might be when speaking to your NET expert at a medical appointment or perhaps a NET expert you meet at an educational conference. Using your NET elevator speech, you can speak NET to better communicate your “NET VITALS.” WHAT SHOULDN’T BE IN YOUR NET INTRO? Words are powerful. We discourage people from identifying themselves or their loved ones as a patient or as a disease. We want to use words that empower and that show we view ourselves as whole people rather than being defined by an illness. Note that your NET Intro is not the same thing as your story. There is a time and a place for telling your story of how you were diagnosed and how NET has impacted you personally. Giving an elevator speech does not replace telling your story; it is a different skill that serves a different purpose. Knowledge is powerful! In this rollercoaster journey where things may sometimes feel out of control, here is something you can control. Learning your NET elevator speech helps you to communicate in the language of NET experts. We can be better patients and advocates by bridging our knowledge gaps and understanding foundational NET terms and concepts. Now go forth and build your own NET elevator speech. Let’s learn to “speak NET” together! DOWNLOAD THE NET INTRO CARD The NET Intro card can be filled out digitally or printed and filled out. Esta página también está disponible en español, se encuentra aquí. RESOURCES If you're not sure what the above terms mean or how to find the differentiation, grade, or ki-67 on your pathology report, we recommend the following resources: NETRF’s NETWise infographic “Stage, Differentiation, & Grade” NETRF’s NETWise podcast Episode 1: What You Need to Know About NETs NET VITALS webinar (starting @14:20) Pathology webinar by Dr. Sue Chang (starting @ 36:43) Symptom Management presentation by Dr. Del Rivero (covers functional tumors and management of carcinoid syndrome) NOTE: NET Intro is a document for personal use only. It is not submitted to nor collected by LACNETS. It is a document for you to fill out and take with you to your physician appointment. This document is intended for informational and educational purposes only and is not a substitute for professional medical advice. Always consult with your physician or health care provider.

Learn more about the NET experts presenting on various topics during the 2023 LACNETS Neuroendocrine Tumor Patient Conference. 2023 LACNETS Conference Speakers NETS 101: OVERVIEW OF NET TERMS & CONCEPTS AMAN CHAUHAN, MD Medical Oncologist, University of Miami Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. A CONVERSATION WITH THREE NET SURGEONS CALLISIA CLARKE, MD Surgical Oncologist, Medical College of Wisconsin Dr. Callisia N. Clarke completed her medical degree at the University of Cincinnati College of Medicine where she was elected to the Alpha Omega Alpha Honors Society. She completed a general surgery residency at the University of Cincinnati Medical Center in Cincinnati, Ohio in 2013 and a fellowship in Complex General Surgical Oncology at The University of Texas MD Anderson Cancer Center in 2016. She joined the faculty at the Medical College of Wisconsin in 2016 as an Associate Professor of Surgery in the Division of Surgical Oncology. Dr. Clarke specializes in hepato-pancreatic-biliary malignancies, melanoma and sarcoma, with her research efforts centered on epigenetic regulation of Neuroendocrine Tumors. She holds numerous leadership positions in national organizations including the American Hepato Pancreato-Biliary Association, the Association for Academic Surgery, the North American Neuroendocrine Tumor Society, and the Society of Surgical Oncology. ALEXANDRA GANGI, MD Surgical Oncologist, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. DANIEL ANAYA SAENZ, MD Surgical Oncologist, Moffitt Cancer Center Dr. Daniel Anaya is a Senior Member, Chief of GI Surgery and Head of Hepatobiliary Section in the Department of Gastrointestinal Oncology, at Moffitt Cancer Center. Dr. Anaya is a fellowship trained Surgical Oncologist with a particular focus on the surgical treatment of patients with liver malignancies (primary and metastatic) and neuroendocrine tumors. His academic interests focus on improving the quality of cancer care and implementing models to improve the delivery of care for patients with complex cancers. He is an expert in developing academic programs that facilitate the delivery of the highest quality of care, while also providing a framework to support research and innovation in the field of cancer and surgery. THE LATEST IN LIVER-DIRECTED THERAPY OSMAN AHMED, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. THE LATEST IN NET IMAGING NADINE MALLAK, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, MD is an Associate Professor of Diagnostic Radiology at Oregon Health and Science University (OHSU), in the divisions of Body Imaging, and Molecular Imaging and Therapy. She is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for neuroendocrine tumors and prostate cancer. THE LATEST IN PRRT CARINA MARI APARICI, MD Radiologist & Nuclear Medicine, Stanford University Health Care Mari Aparici, MD is a Clinical Professor in Radiology at Stanford University. She is a Nuclear Physician with residencies in both Europe (Barcelona) and US (Stanford), and with Molecular imaging fellowships from Stanford University. After her training, she joined the Faculty at UCSF where she became a Clinical Professor in Radiology. Dr Mari Aparici is a physician-scientist in the development of Molecular Imaging and therapies. She has more than 20 years of clinical and research experience in the field and now serves as the Director of the Targeted Radionuclide Therapy Program/Theragnostics Clinic at Stanford University. She has published more than 100 papers, serves as an editorial board member of reputed journals, is PI of NIH and non-NIH grants and serves as a member/chair of several committees at her University and Societies related to her medical specialty. THE LATEST IN SYSTEMIC TREATMENTS & CONSIDERATIONS FOR TREATMENT SEQUENCING PAMELA KUNZ, MD Medical Oncologist, Yale Cancer Center Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine and Director of the Center for Gastrointestinal at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with gastrointestinal (GI) malignancies and neuroendocrine tumors (NETs). She holds key leadership positions in the field including Chair of the Neuroendocrine Tumor Taskforce of the NCI and vice president of the North American Neuroendocrine Tumor Society. In addition, she has emerged as a leading voice for promoting gender equity in the medical workforce and serves as the Vice Chief for DEI for the Section of Medical Oncology at Yale. She was recently awarded the Woman Oncologist of the Year by Women leaders in Oncology. THE LATEST IN NET CLINICAL TRIALS SIMRON SINGH, MD Medical Oncologist, Sunnybrook Health Sciences Center Dr. Simron Singh is an Associate Professor of Medicine, at the University of Toronto and co-founder of the Susan Leslie Clinic for Neuroendocrine Cancers at the Odette Cancer Centre Sunnybrook Health Sciences Centre. In addition, he is a principal investigator and associate scientist with the Institute for Clinical Evaluative Sciences and Sunnybrook Research Institute. He completed his B. Sc as well as MD at University of Alberta in Edmonton, Alberta. He completed postgraduate training in Internal Medicine at Queens University in Kingston, Ontario, Canada and Medical Oncology at the University of Toronto. After completing his clinical training, Dr. Singh completed his Master's degree in Public Health from Harvard University in Boston, MA, USA. In 2013, Dr. Singh joined Cancer Care Ontario/Ontario Health (CCO/OH) as the Provincial Head, Person-Centred Care Strategy, responsible for the development and execution of CCO corporate strategic priority around person-centred care. He’s had numerous other board and administrative roles both at the national and international level. Dr. Singh is the symposium chair for the North American Neuroendocrine Tumor Society as well as the co-chair of the Commonwealth Neuroendocrine Tumour Group. He is the Canadian Clinical Trial group NET disease site group co-chair, as well as on the European Neuroendocrine Tumour Society advisory board. He currently is the co-chair of the Neuroendocrine Advisory Committee at Cancer Care Ontario which has been able to bring PRRT and Ga-68 imaging to Ontario. Dr. Singh is an internationally recognized clinical and research leader in the field of neuroendocrine cancers. He is a leader in health services research and system level quality improvement and measurement. Dr. Singh has been published in numerous high impact journals such as Lancet, Lancet Oncology, JAMA Oncology and the Journal of Clinical Oncology as lead or senior author. He has been the primary author of numerous guidelines to improve the care of NET patients. He holds a number of peer reviewed grants as well as clinical trial leadership positions. Dr. Singh has numerous international speaking invitations as well as leads a number of research and quality initiatives to improve the ongoing care of patients with cancer. CLINICAL TRIALS: WHY, WHAT & HOW JOSH MAILMAN, MBA President, NorCal CarciNET Josh Mailman was diagnosed with PNET in 2007. Josh is an internationally recognized advocate for NET patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging. He is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, Board Member and Treasure of the Neuroendocrine Tumor Research Foundation (NETRF), a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, and president of NorCal CarciNET Community, one of the largest NET patient communities in the United States. He is currently the sole patient rights advocate for the Nuclear Regulatory Commission’s Advisory Committee for the Medical Use of Isotopes (ACMUI). Josh is also a member of National Cancer Institute’s GI Steering Committee and serves as co-chair of the Patient Advocate Steering Committee. In 2015, Josh was honored with the Warner Advocacy Award, given annually by Novartis Oncology Patient Advocacy and The NET Alliance. The award recognizes an individual for leadership and advocacy for neuroendocrine patients. In the same year, Josh was given the SNMMI’s President’s Award for his work on behalf of patients in the nuclear medicine field. Josh is a former executive board member of the Society for Integrative Oncology (SIO) and was named SIO Patient Advocate of Year in 2010. Josh is a frequent and sought-after speaker for his passionate and highly informed perspective on how patients can effectively participate in the process of working with key stakeholders to improve treatments and advance progress for better quality of life and eventual cures. MODERATORS ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. DANENG LI, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. MARY DONLEVY LACNETS Board member and NET Patient Advocate Mary Donlevy joined the LACNETS Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. << Go back to the 2023 Annual Conference Page

NET Quiz TEST YOUR NET KNOWLEDGE QUIZ #31 - UNDERSTANDING FATIGUE & NETS Here’s a short quiz based on NETRF's NETWise Podcast Episode 30: "Understanding Fatigue & NETs." TAKE THE QUIZ QUIZ #30 - MERKEL CELL NETS Here’s a short quiz based on NETRF's NETWise Podcast Episode 29: "Merkel Cell NETs." TAKE THE QUIZ QUIZ #29 - NETS & RACE Here’s a short quiz based on NETRF's NETWise Podcast Episode 27: "NETs & Race." TAKE THE QUIZ QUIZ #28 - GYNECOLOGIC NETS Here’s a short quiz based on NETRF's NETWise Podcast Episode 24: "Gynecologic NETs." TAKE THE QUIZ QUIZ #27 - PARENTING WITH NETS Here’s a short quiz based on NETRF's NETWise Podcast Episode 23: "Parenting With NETs." TAKE THE QUIZ QUIZ #26 - ADJUSTING TO & NAVIGATING THE NEW NORMAL Here’s a short quiz based on NETRF's NETWise Podcast Episode 21: "Adjusting to the New Normal" and Episode 22: "Navigating the New Normal." TAKE THE QUIZ QUIZ #25 - NET RESEARCH (PART 2) Here’s a short quiz based on NETRF's NETWise Podcast Episode 20: “NET Research – Part Two.” TAKE THE QUIZ QUIZ #24 - NET RESEARCH (PART 1) Here’s a six question quiz based on NETRF's NETWise Podcast Episode 19: “NET Research – Part One.” TAKE THE QUIZ QUIZ #23 - HIGH-GRADE NETS AND NECS Here’s a five question quiz based on NETRF's NETWise Podcast Episode 18: “High-Grade NETs and NECs.” TAKE THE QUIZ QUIZ #22 - LIVER NETS Here’s a five question quiz based on NETRF's NETWise Podcast Episode 17: "Focus on Liver NETs." TAKE THE QUIZ QUIZ #21 - NETS AND NUTRITION Here’s a five question quiz based on NETRF's NETWise Podcast Episode 16: “NETs and Nutrition.” TAKE THE QUIZ QUIZ #20 - SUPPORTIVE CARE FOR THE MIND, BODY, AND SOUL Here’s a five question quiz based on NETRF's NETWise Podcast Episode 15: “Supportive Care for the Mind, Body, and Soul.” TAKE THE QUIZ QUIZ #19 - PHEOS & PARAS Here’s a six question quiz based on NETRF's NETWise Podcast Episode 14: “Pheos & Paras.” TAKE THE QUIZ QUIZ #18 - NETS AND GENETIC SCREENING Here’s a six question quiz based on NETRF's NETWise Podcast Episode 13: “NETs and Genetic Screening.” TAKE THE QUIZ QUIZ #17 - THE IMPORTANCE OF CAREGIVING Here’s a five question quiz based on NETRF's NETWise Podcast Episode 12: "The Importance of Caregiving." LACNETS’ Program Director and a NET caregiver, Lisa Yen, is a guest on this episode! TAKE THE QUIZ QUIZ #16 - AYA (ADOLESCENTS & YOUNG ADULTS) AND NETS Here’s a four question quiz based on NETRF'w NETWise episode 11, "AYA (Adolescents and Young Adults) and NETs." TAKE THE QUIZ QUIZ #15 - SMALL BOWEL NETS Here’s a five question quiz based on NETRF'w NETWise special episode, "Small Bowel NETs.” TAKE THE QUIZ QUIZ #14 - PANCREATIC NETS Here’s a seven question quiz based on NETRF's NETWise episode #10, “Pancreatic NETs.” TAKE THE QUIZ QUIZ #13 - LUNG NETS Here’s a six question quiz based on NETRF's NETWise special episode, “Lung NETs.” TAKE THE QUIZ QUIZ #12 - CLINICAL TRIALS Here’s a six question quiz based on NETRF's NETWise podcast episode, “Clinical Trials.” TAKE THE QUIZ QUIZ #11 - MANAGING SYMPTOMS OF NETS Here’s a seven question quiz based on NETRF's NETWise podcast episode, “Managing Symptoms of NETs.” TAKE THE QUIZ QUIZ #10 - MEDICAL MANAGEMENT OF NETS Here’s a seven question quiz based on NETRF's NETWise podcast episode, “Medical Management of NETs: Understanding SSAs, Chemotherapy, and Targeted Therapy” . TAKE THE QUIZ QUIZ #9 - NUCLEAR MEDICINE FOR NETS: WHAT IS PRRT? Here’s a quick six question quiz based on NETRF's NETWise podcast episode, “Nuclear Medicine for NETs: What is PRRT?” TAKE THE QUIZ QUIZ #8 - COVID-19 AND NETS Here’s a quick seven question quiz based on NETRF's NETWise podcast episode, “COVID-19 and NETs.” TAKE THE QUIZ QUIZ #7 - SURGERY AND INTERVENTIONAL RADIOLOGY FOR NETS Here’s a six question quiz based on the NETRF's NETWise podcast episode #3, “Surgery and Interventional Radiology for NETs.” TAKE THE QUIZ QUIZ #6 - IMAGING, TESTING, & BUILDING A CARE TEAM (PART 2) Here’s a six question based on NETRF's NETWise podcast episode #2: “Imaging, Testing, and Building a Care Team.” TAKE THE QUIZ QUIZ #5 - IMAGING, TESTING, & BUILDING A CARE TEAM (PART 1) Here’s a quick five question quiz based on NETRF's NETWise podcast episode #2: “Imaging, Testing, and Building a Care Team.” TAKE THE QUIZ QUIZ #4 - WHAT YOU NEED TO KNOW ABOUT NETS We put together a quick quiz based off of the first episode of NETRF’s NETWise podcast, “What You Need to Know About NETs. ” TAKE THE QUIZ QUIZ #3 - REVIEW NET BASICS Review your NET basics by taking this five question quiz! This quiz is just a fun way to learn! If you get it wrong, don't stress! Now you know the correct answer! TAKE THE QUIZ QUIZ #2 - LEARN TO SPEAK NET LACNETS put together a quick five question quiz to help you learn to speak NET! TAKE THE QUIZ QUIZ #1 - TEST YOUR KNOWLEDGE ON NET In honor of Rare Disease Day 2019, LACNETS put together a quick four-question quiz to test your knowledge on neuroendocrine cancer! TAKE THE QUIZ

Para los recién diagnosticados COMPLETE EL FORMULARIO DE PACIENTE/CUIDADOR AQUÍ - ÚNASE A LACNETS Te acaban de informar que tienes un Tumor Neuroendocrino, Cáncer Neuroendocrino o Carcinoide. Lo primero que sentimos puede ser pánico, incredulidad, desesperación o quizás una sensación de alivio al haber sido finalmente diagnosticado. Después del impacto inicial, cuando volvemos a pensar claramente, nos viene a la mente la pregunta "¿y ahora qué?" Toma el control, conviértete en tu defensor y en líder de tu equipo de salud. Esta es una guía para los recién diagnosticados con NETs, donde podrás encontrar consejos y datos útiles. NOTAS: Todos los recursos marcados con * están únicamente disponibles en Ingles. Para instrucciones en como activar subtítulos en español en los videos de YouTube haz clic aquí. 7 CONSEJOS PARA EL PACIENTE RECIÉN DIAGNOSTICADO (Haga clic para desplazarse hacia abajo y obtener más información sobre cada consejo.) 1. ORGANÍZATE 2. EDÚCATE SOBRE LA ENFERMEDAD Y APRENDE A HABLAR “NET” 3. BUSCA APOYO 4. BUSCA UN ESPECIALISTA EN NETS 5. DECIDE QUIÉN SERÁ TU MARISCAL DE CAMPO 6. ASISTE A UNA CONFERENCIA DE EDUCACIÓN PARA PACIENTES CON NETS 7. RESPIRA PROFUNDO 7 HECHOS SOBRE LOS NETs 1. EL CÁNCER NEUROENDOCRINO TAMBIÉN SE CONOCE COMO TUMOR NEUROENDOCRINO. 2. LOS NETS SON UN TIPO DE CÁNCER RARO QUE AFECTA APROXIMADAMENTE A 6,98 DE CADA 100.000 PERSONAS. 3. LOS NETS PUEDEN AFECTAR LAS CÉLULAS NEUROENDOCRINAS EN TODO EL CUERPO. 4. LOS NETS SON DIFÍCILES DE DIAGNOSTICAR. 5. NO TODOS LOS PACIENTES CON NETS TIENEN SINTOMAS. 6. LA CAUSA ES DESCONOCIDA. 7. ES MUY IMPORTANTE BUSCAR LA OPINIÓN DE UN ESPECIALISTA EN NETS. 1. ORGANÍZATE NET VITALS* es un excelente lugar para comenzar. NET VITALS es un documento descargable con la información más importante que los pacientes y los profesionales de la salud necesitan saber sobre el Cáncer Neuroendocrino. Su propósito es servir como una herramienta de comunicación médico-paciente, como un “Pasaporte NET” que contiene toda la información importante y que puedes llevar a todas tus citas con el médico. Si bien no es un documento médico, ha sido revisado por especialistas en NETs que están de acuerdo en lo útil que puede ser que los pacientes completen sus NET VITALS* antes de su cita. Nota: NET VITALS únicamente tiene fines informativos y educativos. LACNETS no recopila ni almacena sus NET VITALS. Solo para su uso personal. NET VITALS puede ayudar de la siguiente manera: A prepararte para tu cita con tu especialista en NETs. A aprender de tu enfermedad y a entender cómo esta información se relaciona contigo. A organizar y recopilar la información y los registros relevantes para la próxima cita con tu especialista en NETs. A aclarar y formular las preguntas que tengas para tu(s) médico(s). A ayudar para que tu próxima cita sea más eficiente. Cómo llenar NET VITALS: Descarga NET VITALS aquí. * Ve el seminario web de NET VITALS aquí.* Cuando encuentres términos y tratamientos que no te sean familiares, consulta los recursos en la última página del documento NET VITALS. CNETS proporciona una excelente guía comprensiva para pacientes, la puedes encontrar aquí . (Disponible en inglés y francés) Completar NET VITALS puede ayudar a identificar la información que necesite ser clarificada por tu especialista en NETs y te ayuda también a crear una lista de preguntas relevantes para la próxima cita con tu especialista en NETs. Lleva el documento a las citas con tu especialista en NETs. Es probable que tendrás que actualizarlo a medida que vayas teniendo nueva información. CONSEJOS PARA EL ALMACENAMIENTO DE REGISTROS (consulte NET VITALS* para obtener una lista de información médica importante): Muchas personas eligen guardar y organizar su información en papel, ya sea en carpetas de archivos, cuadernos o blocks de notas. Si guardas copias en papel de resultados de laboratorio, reportes de imágenes, informes de patología, etc., considera escanearlos a tu computadora. ¡Esto no solo facilita el acceso a tus registros, sino que también evita que pierdas la información si la copia en papel se pierde o es dañada. Almacenar tus registros en forma digital, ya sea en tu computadora o en un servicio en la nube, puede ser útil si deseas enviar información electrónicamente, como al pedir una segunda opinión. Algunas personas realizan su seguimiento de los resultados de laboratorio en una hoja de cálculo para así poder hacer comparaciones y seguir su progreso. Elijas lo que elijas, ¡organización es la clave! Tener todo almacenado en un mismo lugar es muy importante. Además, la información debe ser fácil de acceder y de compartir con tu equipo médico cuando sea requerido. Después de cada escaneo, vaya a la oficina de registros médicos o a la librería de imágenes y solicita un CD con las imágenes escaneadas para tus archivos. A la vez, solicita una segunda copia para tu especialista en NETs o para pedir una segunda opinión. Nunca entregues tu única copia de un CD o de cualquier documento. Después de cualquier biopsia o cirugía, solicita a tu médico una copia del informe de patología. (Estos a veces no se encuentran en los portales electrónicos para pacientes, por lo que es posible que sea necesario solicitar una copia) De la misma manera, después de cualquier cirugía o procedimiento, solicita el informe operatorio o el informe del procedimiento. (Estos a veces no se encuentran en los portales electrónicos para pacientes, por lo que es posible que sea necesario solicitar una copia) 2. EDÚCATE SOBRE LA ENFERMEDAD: APRENDE A HABLAR “NET.” Ve la presentación "Tratamiento de Tumores Neuroendocrinos Avanzados" con la Dra. Jaydira Del Rivero Ve la presentación informativa "Qué esperar de una consulta con un experto de NET” por la Dra. Heloisa Soares del Instituto del Cáncer Huntsman. Ve el seminario web de LACNETS, "Secuencias de tratamientos de Tumores Neuroendocrinos *" con el Dr. Eric Liu, cirujano general y especialista Neuroendocrino del Rocky Mountain Cancer Center. Consulta los recursos para los recién diagnosticados* de NorCal CarciNET: Lista de verificación* para los recién diagnosticados. Consejos en video para los recién diagnosticado* por Josh Mailman, presidente de NorCal CarciNET. Consulta los valiosos recursos para los recién diagnosticados de Triage Cancer: Descarga la "Lista de verificación: Cómo organizarse ” Descarga la “Lista de verificación para evitar toxicidad financiera ” Descarga la "Derechos sobre el cáncer: lidiar con el empleo, el seguro médico y las finanzas " Descarga los folletos digitales proporcionados por la Allianza Internacional del Cancer Neuroendocrino (INCA). Al acceder esta pagina, selecciona “Español” en el submenú ubicado debajo de “Please choose your lenguaje” y presiona el botón “Go!” Lee estos 10 HECHOS* sobre los NETs. La Red Integral Nacional del Cáncer* (NCCN, por sus siglas en inglés) es una alianza de los principales centros oncológicos de Estados Unidos que desarrolla y publica las pautas de práctica actualizadas y basadas en evidencia llamadas Pautas de NCCN* . Estas pautas cuentan con el respaldo de Carcinoid Cancer Foundation, Healing NET Foundation, NCAN y NETRF. Debido a que estas se reconocen como el estándar en la atención del cáncer, es un recurso esencial para las conversaciones con tu equipo médico. También son una excelente referencia para cuando se deben hacer reclamaciones de seguros. Ordena la guía gratuita de Cáncer Neuroendocrino para Pacientes y Familiares* , publicada por NETRF. Ordena o descarga la publicación de The Healing NET Foundation, titulada “Navegando el Viaje del Paciente NET”*. Descarga esta guía completa para pacientes y familiares , cortesía de CNETS Canadá. (Disponible en Inglés y Francés) Únete a un grupo educativo o de apoyo de NETs* . Suscríbete a sus boletines para recibir las últimas actualizaciones sobre NETs y las próximas reuniones. Asiste a reuniones y conferencias educativas para establecer contactos con especialistas y otros pacientes. Suscríbete al canal de YouTube de LACNETS y ve videos de anteriores reuniones educativas en la extensa biblioteca de LACNETS en YouTube , en donde también podrás encontrar nuestra lista de videos en Español. Nota sobre la prognosis: Una pregunta muy común es: "¿Cuánto tiempo me queda para vivir?" Es común enterarnos de historias de pacientes a los que su médico les dijo que solo tenían unos meses de vida y que deberían de “poner sus asuntos en orden” En contraste, los especialistas en NETs a menudo dicen: "No sabemos cuánto tiempo tienes” Cuanto más aprendas sobre los NETs, más aprenderás que es muy difícil formular una prognosis. Los NETs son impredecibles y el caso de cada persona es único, por lo que suele ser difícil hacer una predicción. Además, muchas de las estadísticas que existen en la red no están actualizadas. Han habido muchos avances recientes en investigación de los NETs que han llevado a una detección más temprana y más opciones de tratamiento. Como resultado, los pacientes viven más tiempo con la enfermedad. Muchas personas dentro de la comunidad NET viven con esta enfermedad desde hace más de una década. 3. BUSCA APOYO Únete a un grupo de apoyo local y asiste a reuniones de educación para pacientes con NETs. A menudo escuchamos a la gente decir: "Pensé que era el único con esta enfermedad" Conectar con otros pacientes puede ayudarte a no sentir soledad. Lee historias inspiradoras* de otros pacientes con NETs o de las personas a cargo de sus cuidados. Conéctate con otro paciente para aprender de su experiencia. Haz clic aquí* para conectarte con otro paciente o con una persona a cargo de cuidados de pacientes con NETs. Busca y únete a un grupo de apoyo de NETs local. Son excelentes como recursos de apoyo y como fuentes de información y educación. Haz clic aquí* para obtener un directorio de grupos de apoyo de NET. Busca y suscríbete a un grupo de apoyo en línea. Haz clic aquí* y aquí* para obtener un directorio de grupos de discusión y apoyo en línea. CONSEJO: Los grupos de apoyo suelen ser una buena fuente de información acerca de reuniones educativas y recursos para los pacientes y sus familias. Podemos aprender mucho de las experiencias de los demás. Algunos pacientes incluso informan que encontraron a su(s) especialista(s) en NETs por medio de un grupo de apoyo. 3. BUSCA APOYO Estudios recientes (puedes leer algunos aquí* y aquí *) muestran que los pacientes con NETs que son atendidos por un equipo multidisciplinario, tienden a tener mejores resultados. Por lo general, los centros de atención especializada en NETs pueden diagnosticar y tratar los NETs de manera más rápida y precisa. Es mejor tener un enfoque multidisciplinario en el que un equipo de especialistas en NETs, con diferentes áreas de especialización, se reúne y revisa tu caso. Esto a menudo se lleva a cabo en una junta de tumores, donde cada caso es discutido y revisado por varios médicos, incluyendo oncólogos, endocrinólogos, gastroenterólogos, cirujanos, radiólogos, médicos nucleares y patólogos. (Dado que no se permite que los pacientes estén presentes en estas juntas, puedes ver aquí* el video de una junta de tumores simulada en una conferencia de LACNETS y darte una idea de cómo son) ONCÓLOGOS ESPECIALIZADOS EN NETS EN EL ÁREA DE LOS ÁNGELES: Dr. Randy Hecht UCLA (oficina de Santa Mónica), Oncólogo Médico (GI) 2020 Santa Mónica Blvd. Suite 600, Santa Mónica, CA Teléfono: 310-829-5471 Dr. Andrew Hendifar Cedars-Sinai, Oncólogo Médico 8700 Beverly Blvd, #LL North Tower, Los Ángeles, CA 90048 Teléfono: 310-423-2217 Dr. Daneng (Dan) Li City of Hope, Oncólogo Médico Co-director del Programa de Tumores Neuroendocrinos en City of Hope 1500 E. Duarte Road, Duarte CA 91010 (cerca de Pasadena) Teléfono: 800-826-4673 PARA ENCONTRAR UN ESPECIALISTA EN NETS FUERA DE LOS ÁNGELES: El Directorio de especialistas en NETs* publicado por Carcinoid Cancer Foundation es un buen lugar para comenzar. *CONSEJO: Muchos de los especialistas en NETs (incluyendo oncólogos, cirujanos, endocrinólogos, etc.) han sido oradores en conferencias y reuniones para pacientes con NETs. Puede ser útil buscar en los canales de YouTube o Vimeo de grupos como LACNETS , NorCal CarciNET y NETRF para encontrar videos de especialistas en NETs que puedas estar considerando para una segunda opinión. Puede ser útil "ver" al médico antes de tu cita. 5. DECIDE QUIÉN SERÁ TU MARISCAL DE CAMPO Los pacientes a menudo vemos varios médicos con diferentes áreas de especialización y a menudo obtenemos opiniones de varios expertos en NETs. Es importante encontrar a alguien en quien confíes, que sabes que va a escuchar y responder a tus inquietudes, que explique las cosas de una manera clara y sencilla y que conozca y aplique los tratamientos que necesitas. Debes encontrar a alguien con quien sientas que puedes trabajar y que sientas que está dispuesto a trabajar contigo. Una vez que hayas reunido a tu equipo médico, decide quién será el que dirigirá al equipo y estará a cargo de tomar las decisiones. 6. ASISTE A UNA CONFERENCIA DE EDUCACIÓN PARA PACIENTES CON NETS Los grupos de apoyo son una gran fuente de información para los pacientes con NETs. Algunos de estos grupos, incluyendo a LACNETS y a NorCal CarciNET, organizan conferencias anuales para pacientes y personas a cargo de sus cuidados. Las fundaciones de NETs como Carcinoid Cancer Foundation , HealingNET y NETRF también participan en conferencias educativas. Regístrate para recibir sus boletines y visita sus sitios web para conocer donde y cuando seran las próximas conferencias. Si bien algunas de estas conferencias se pueden ver de forma remota a través de transmisiónes en vivo y los videos de conferencias anteriores están disponibles en línea, vale la pena asistir a las conferencias en persona, ya que hay oportunidades para interactuar con especialistas, pacientes y otras personas de la comunidad. Próximas reuniones de LACNETS * Fundación del Cáncer Carcinoide * Fundación HealingNET * NCAN * NETRF * NorCal CarciNET * 7. RESPIRA PROFUNDO Haga clic aquí para leer la publicación completa. No olvides respirar. Toma un descanso. Recuerda que la razón por la que tratamos de educarnos es para VIVIR. Para la mayoría de nosotros, vivir con NETs es más un maratón que una carrera de velocidad. Algunas personas sienten que deben pasar cada minuto del día aprendiendo sobre la enfermedad para no perderse de algo que podría ser la diferencia entre la vida o la muerte. Para la mayoría de los pacientes con NETs eso, simplemente, no es asi. Además es igual de importante cuidar de nuestra salud emocional, mental y espiritual como lo es cuidar de nuestra salud física. Por lo tanto, si te sientes abrumado, es una buena idea tomar un descanso y hacer algo que te dé vida y que no esté relacionado con el cáncer. Disfruta de placeres o actividades simples como salir a caminar, ir a la playa, jardinería, ver una película, ir a un museo o un concierto, etc., y cuando te sientas revitalizado y descansado estarás listo para continuar tu educación y obtener más información sobre los NETs. Es sorprendente lo relajante y lo saludable que es el tomar un minuto de tiempo y respirar. (Haz clic aquí* para leer nuestra publicación titulada "Respira"). 1. El Cáncer Neuroendocrino también se conoce como Tumores Neuroendocrinos o NETs por sus siglas en inglés. Estas son las diversas terminologías que puedes encontrar: Neoplasia neuroendocrina (NEN): Es el término médico oficial que se ve a menudo en la literatura médica, como en la clasificación de NEN de la Organización Mundial de la Salud (OMS). NEN incluye tanto NETs como los Carcinomas Neuroendocrinos (NECs). NECs también se conocen como Cáncer Neuroendocrino de "alto grado". Los NECs se tratan de manera diferente a los NETs. Puedes encontrar más información específica de NECs aquí*. Carcinoide: Este es un término antiguo que significa “similar al cáncer” Este término está cayendo en desuso ya que no es preciso. Los NETs no son similares al cáncer, son cáncer. Aunque algunas veces pueden ser benignos (lo que significa que no se ha propagado desde donde se originó), la mayoría son malignos (lo que significa que se ha propagado a un lugar diferente al origen). Es posible que aún escuches que algunos médicos se refieren a los NETs que se originan fuera del páncreas, como en el pulmón o en el intestino delgado, como tumores carcinoides. Cáncer Neuroendocrino: Este es un término que es usado a menudo por las organizaciones de defensa de pacientes para referirse a las NENs (NETs o NECs), ya que crea conciencia sobre el hecho de que los NETs no son un tipo de Cáncer benigno, como se pensaba anteriormente. Otros términos que puedes escuchar se refieren al sitio del tumor primario (p. ej., PNET o NET pancreático) o la hormona que secreta el tumor (p. ej., Insulinoma o VIPoma). 2. Los NETs es tipo raro de Cáncer que afecta aproximadamente a 6.98 de cada 100.000 personas *. 3. Los NETs pueden afectar las células neuroendocrinas que existen en todo el cuerpo. Estas son células productoras de hormonas que se encuentran, más comúnmente, en el sistema gastrointestinal (estómago, intestino delgado, intestino grueso, recto), en los pulmones y en el páncreas. A menudo se propagan a los ganglios linfáticos, al hígado y a los huesos. Los tumores que se forman a causa de esta propagación reciben el nombre de Metástasis. 4. Los NETs son un Cáncer que es difícil de diagnosticar. Esto se debe a que no todas las personas con NETs tienen síntomas. Para aquellos que sí tienen síntomas (menos de la mitad de todos los pacientes con NETs), estos síntomas son vagos e incluyen bochornos, diarrea, náuseas, calambres abdominales, inflamación abdominal, gas y dificultad para respirar. 5. Algunos pacientes con NETs tienen síntomas. (Pero no todos.) Por lo general, solo los pacientes que tienen tumores productores de hormonas, llamados tumores funcionales, tienen síntomas. Estos síntomas se denominan Síndrome Carcinoide. 6. La causa es desconocida. Muchas personas a menudo se preguntan si hicieron algo para causar su cáncer. La respuesta es no. Aunque hay algunos tipos de NETs que tienen un vínculo genético, la mayoría no tiene una causa conocida. 7. Es muy importante buscar la atención de un especialista en NETs. La mayoría de los diagnósticos de Cáncer Neuroendocrino no los hace un especialista en NETs. La mayoría de los pacientes terminan buscando una segunda opinión con un especialista en NETs, teniendo a veces que viajar fuera del área en la que viven. Debido a que los NETs son raros, no todos los médicos tienen el conocimiento adecuado de la enfermedad, ni de los avances recientes en diagnostico y tratamiento. Un especialista en NETs puede ayudarte mejor a guiar tu plan de tratamiento. El especialista en NETs puede trabajar con tu médico para controlar tus síntomas, la enfermedad y recomendar los tratamientos más adecuados. De acuerdo con una encuesta hecha a gran escala con pacientes con NETs, aquellos que reciben atención en un centro especializado en NETs se sienten significativamente más satisfechos con su tratamiento y están mejor informados sobre las diferentes opciones de tratamiento que aquellos que no visitan centros especializados en NETs. *Original site translated by Michel DeQuevedo from NET Mexico (@NETs Mexico). 7 HECHOS ACERCA DE LOS NETs

Imaging Resources PODCAST Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. Listen Here EDUCATIONAL WEBINARS "Understanding NET Scans" with Nadine Mallak, MD "The Latest in NET Imaging" with Nadine Mallak, MD "NET Imaging: Demystifying Scans and Reports" with Gary A. Ulaner, MD "The Latest in NET Imaging & PRRT" with Thomas Hope, MD "Exciting Advances in NET Management: Cu64 DOTATATE & Alpha PRRT" with Ebrahim S. Delpassand, M.D., F.A.C.N.M. ADDITIONAL IMAGING RESOURCES Detectnet Patient Brochure by Curium Detectnet is used with a PET scan to help diagnose possible NETs A Guide to Understanding Neuroendocrine Tumors (NETs) and the Role of Imaging NANETS NET GUIDELINES 2017 (Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Recursos en Español Información en Español Aquí hay recursos útiles en español para pacientes y cuidadores con tumores neuroendocrinos. A continuación, encontrará videos educativos, grupos de apoyo, historias de pacientes y cuidadores, información útil sobre seguros medicos y otros servicios de apoyo. Haga clic aquí para obtener recursos para los recién diagnosticados. Para comunicarse con LACNETS, envíe un correo electrónico a info@LACNETS.org . Tenga en cuenta que no podemos responder en español. Lo sentimos. Presentaciones Educativas Presentaciones Educativas Mas Videos en español Download "Comprensión de las Guías de losTumores Neuroendocrinos (TNEs)" Presentation Slides >>> Download "Actualizaciónes en los Tumores Neuroendocrinos" Presentation Slides >>> Click here to download the presentation slides. Historias de Pacientes Historias de Pacientes Michél vive con cáncer neuroendocrino. Escuche su historia inspiradora y cómo mantiene la esperanza. ver el vídeo Historias de Pacientes y Cuidadores Historias de Pacientes y Cuidadores Introducción NETs Introducción NETs La “Presentación NETs de Elevador” es una forma de presentarte. La razón por la que se llama de “Elevador" es porque debe ser lo suficientemente breve para poder decirla durante un viaje en elevador. Aprende más aquí Tumores neuroendocrinos Cancer.NET ofrece información sobre los tumores neuroendocrinos. Aprende más aquí Guías ASCO Terapia sistémica para control de tumores en tumores neuroendocrinos gastroenteropancreáticos bien diferenciados metastásicos Publicado antes de su impresión el 29 de septiembre de 2023, DOI: 10.1200/JCO.23.01529 Haga clic aquí "El notorio Feo/Para" - Escrito por Aimee Powell - 23 de agosto de 2021 Información Adicional Información Adicional Un analisis del cancer neuroendocrino The Carcinoid Cancer Foundation proporciona un analisis del cancer neuroendocrino. Haga clic aquí Recursos en español - videos, materiales, y seminarios web Triage Cancer tiene información disponible en español. Haga clic aquí. Haga clic aquí Cancer Support Community Los Angeles - grupos de apoyo CSC ofrece varios grupos de apoyo para pacientes y cuidadores. Haga clic aquí INCA - videos y guías educativas INCA tiene mas información en español sobre tumores neuroendocrinos. Haga clic aquí. Descargue el paquete de información para pacientes de Global NET - haga clic aquí. UCLA Health - meditación guiada UCLA ofrece sesiones de meditación guiadas en español. Haga clic aquí La Sociedad Estadounidense de Oncología Clínica Información confiable y compasiva para personas con cáncer, sus familiares y sus cuidadores, de parte de expertos de la American Society of Clinical Oncology (la Sociedad Estadounidense de Oncología Clínica, ASCO por sus siglas en inglés), la voz de los médicos del cáncer y los profesionales oncológicos del mundo. Haga clic aquí

Wellness < Back to Topics Nutrition Nutrition Play Video Play Video 45:40 Episode 29: Nutrition & Diet Considerations for NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. MEET SINA TESKEY, RD, CD Sina Teskey, RD, CD received her B.S. from the University of Wisconsin-Madison in 2006 and completed her dietetic internship at the University of Minnesota Medical College-Fairview in 2007. She has spent most of her career working with cancer and eating disorder patients. Sina practiced in the Twin Cities area for 10 years where she also spent time guest starring on a local TV show called Twin Cities Live to share nutrition advice. She moved to Milwaukee and has worked at Froedtert Hospital and the Medical College of Wisconsin since 2018. Sina sees all patients with cancer but specializes in GI cancers and neuroendocrine tumor patients. When she’s not working, Sina is a mom to three kids and a Labrador retriever. She loves to cook and bring people together with food. Her youngest son was diagnosed with Non-Hodgkin’s Lymphoma in 2019. His cancer journey gave insight into what having cancer means to a family and has impacted her practice profoundly. Her son Milo is now 7 years old and in remission. TOP TEN QUESTIONS 1. Is there a diet NET patients should follow? Are there foods NET patients should avoid? Some people say there are certain “trigger foods” to avoid. What CAN I eat? 2. What diet is helpful after bowel surgery? What about pancreas surgery? 3. Are there vitamins or supplements recommended for NET patients? 4. What can NET patients do about diarrhea? What diet or medications might help? 5. What can NET patients do if they struggle with a poor appetite? 6. What can NET patients do if they are struggling to keep on or gain weight? 7. What can NET patients do to stay hydrated? 8. What are pancreatic enzymes and how are they taken? Who are they recommended for? 9. What proteins can people take if they are vegetarian or vegan given soy may be a trigger for carcinoid syndrome? 10. What do you think of alternative diets such as the keto diet or other “special diets?” Does sugar feed cancer? What about intermittent fasting? For more information, visit https://www.lacnets.org/podcast/29. Play Video Play Video 29:50 Episode 1: Nutrition for NETs • The LACNETS Podcast ABOUT THE EPISODE For our very first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, recommended diet for NET patients, and much more! MEET THE SPEAKER Meghan Laszlo is a Registered Dietitian (R.D.) and a Board-Certified Specialist in Oncology Nutrition (C.S.O.) at Cedars Sinai’s Samuel Oschin Cancer Center. As an outpatient dietitian, she provides medical nutrition therapy to patients through nutrition counseling, education, and coordination of care. Meghan is fascinated by the nutritional aspects of gastrointestinal, neuroendocrine, and head and neck cancers and is dedicated to helping patients meet their individualized goals. In October 2019, Meghan gave a presentation for LACNETS titled "Nutrition for NETs." TOP NET NUTRITION QUESTIONS 1. What kind of diet benefits NET patients? 2. Which foods cause carcinoid syndrome symptoms? 3. Which foods make diarrhea better and worse? 4. What kinds of fluids and how much are needed with diarrhea? 5. Which dietary supplements are beneficial for NET patients? 6. What is niacin and why is it important for individuals with carcinoid syndrome? 7. How does fat malabsorption effect digestion? 8. How do I know if the prescription enzymes are working? 9. What is small intestinal bacterial overgrowth (SIBO)? For more resources and a transcript of this episode, visit https://www.lacnets.org/podcast1. Play Video Play Video 01:04:20 LACNETS - "Nutrition Therapy for NETs" with Meghan Laszlo (Cedars-Sinai) LACNETS meeting, "Nutrition Therapy for NETs" Tuesday, October 8th Venue: Cedars-Sinai Medical Center The discussion focuses on trigger foods, Carcinoid Syndrome, and more. SPEAKER: Meghan Laszlo, MS, RD, CSO www.LACNETS.org Play Video Play Video 01:35:02 LACNETS Webinar: "Nutrition and Neuroendocrine Cancer" with Tara Whyand, NET Dietician Diet is one of the biggest concerns for NET patients. If you have questions about the foods you should or shouldn't be eating, this is the webinar for you! Join LACNETS & Tara Whyand, NET Nutritionist, for her presentation on "Nutrition & Neuroendocrine Cancer." Recorded on February 16th, 2021. Speaker: Tara Whyand, MSc, BSc NET Dietician To learn more about LACNETS, visit www.LACNETS.org. Audio/Video - www.TVPlive.com Wellness Wellness Play Video Play Video 23:52 Meditation with Ruth Wolever • 2024 LACNETS Wellness Retreat • "The Power of Play" Join Ruth Wolever for a meditation session. This is a recording from the 2023 LACNETS Wellness Retreat: The Power of Play held on Feb 17, 2024. Play Video Play Video 48:33 Episode 18: Mental Health & NETs ABOUT THIS EPISODE What are the common mental health issues associated with NET? How can they be managed? How does NET impact young adults, NET patients and children of NET patients? Health psychologist Dr. Kersting of the Medical College of Wisconsin elaborates on mental health challenges facing NET patients and their loved ones. Hear coping strategies for anxiety, eating and sleeping difficulties, fatigue and depression. Dr. Kersting discusses what you can expect when meeting a mental health professional and why supporting your mental health is an integral part of your overall care. MEET THE SPEAKER Dr. Karen Kersting, Psychologist, Assistant Professor in the Department of Surgery at Medical College of Wisconsin Karen Kersting, PhD, is a licensed clinical psychologist who provides counseling and psychotherapy to patients treated by surgeons in the Division of Surgical Oncology at the Medical College of Wisconsin. She completed an undergraduate degree in Journalism at the University of Wisconsin—Madison, a PhD in Counseling Psychology at Virginia Commonwealth University in Richmond, VA, and a postdoctoral fellowship in clinical health psychology at the Dayton Veterans Administration Medical Center in Dayton, OH. She joined the faculty of MCW in 2016. Dr. Kersting’s research interests include the development and assessment of integrated psychosocial services for people coping with cancer diagnosis and treatment, with an emphasis on patients diagnosed with cancer of the pancreas. Additionally, her work aims to highlight issues related to social determinants of health and Acceptance and Commitment Therapy interventions. TOP 10 QUESTIONS 1. How common are mental health issues in NET patients? What are the most common mental health issues you see in NET and what can be done about it? 2. How does anxiety impact NET patients? Why is it so prevalent in these patients? When do I know I need to reach out for support with my anxiety? What does treatment for anxiety look like? 3. How does depression impact NET patients? 4. What kind of sleep problems do you see in NET patients? 5. How do you work with patients who have long periods of fatigue? 6. How can a psychologist help people who are struggling to eat after treatment? 7. How can a patient, loved one, or physician tell the difference between a symptom such as fatigue or anxiety caused by NET tumors vs. a psychological trigger? Does it matter? How does one’s mental health impact one’s NET disease or the effectiveness of treatments? 8. Discuss how NET may impact young adult NET patients? How does NET impact young adult children, teenagers, and young children of NET patients? 9. Who should see a psychologist? When should someone see a psychologist? How does one find a psychologist? What should a patient expect when they come for a first visit with a mental health professional such as a psychologist, therapist, social worker or other? 10. What coping strategies or advice do you have for NET patients? What coping strategies or advice for family members or loved ones? For more resources and a transcript of this episode, visit https://www.lacnets.org/podcast18. Play Video Play Video 59:50 Episode 15: Psycho-Oncology ABOUT THIS EPISODE What is psycho-oncology and how can it benefit those living with NET? Psychiatrist Dr. Mona Mojtahedzadeh of Simms/Mann UCLA Center for Integrative Oncology discusses whole-person care for cancer patients and caregivers. From “scanxiety” to sleep hygiene, she acknowledges the range of challenges of living with cancer and shares solutions to improve mental well-being and overall health. MEET DR. MONA MOJTAHEDZADEH Mona Mojtahedzadeh, MD, is a psychiatrist at Simms-Mann/UCLA Center for Integrative Oncology, which allows her to continue to perform a work of meaning within a valued population who embrace her into some of their most pivotal moments along their cancer illness trajectory. Dr. Mojtahedzadeh is board certified in Psychiatry as well as in Consultation-Liaison Psychiatry. She obtained her MD from Tehran, Iran’s Shahid Beheshti University of Medical Sciences. She was a general and family practitioner at an underserved health and urgent care clinic in Iran. She completed her psychiatry training through residencies at Texas Tech University Health and Science Center coupled with Loma Linda University Health, where she was granted the department’s research award of the year. She completed a consultation-liaison (C-L) psychiatry fellowship at the University of Southern California and Los Angeles County (LAC+USC) and later served as an Assistant Professor in the Department of Supportive Care Medicine at City of Hope National Medical Center and an Adjunct Assistant Professor of Psychiatry at USC. Her scholarly work includes over 32 publications, posters, and book chapters in areas of medicine, mental health, and their overlap. TOP 10 PSYCHO-ONCOLOGY QUESTIONS 1. Who might seek a psychiatrist? How does one go about finding a psychiatrist that is right for him or her? 2. What is psycho-oncology? If someone living with NET is looking for a psychiatrist, should they seek someone who has trained in psycho-oncology? How does one find such a person? 3. How do you determine if symptoms such as depression, anxiety, mood swing, or fatigue are symptoms caused by their NET cancer or not? 4. Is it safe for NET patients, particularly those with high levels of serotonin, to take antidepressants such as SSRIs that may increase levels of serotonin? 5. If someone living with NET struggles with depression, what is your approach? How do you determine the best treatment option? 6. If someone living with NET struggles with anxiety, how would you approach this patient and how might you manage it? 7. If someone living with NET struggles with sleep issues, what might your thoughts be? 8. What suggestions might you have for loved ones of someone living with cancer who is trying to support someone struggling with depression, anxiety, or mood swings? 9. What suggestions do you have for coping with one’s cancer diagnosis? How might one find some stability and peace during what often feels like a rollercoaster ride? 10. What last words of hope would you leave with the audience? For more resources and a transcript of this episode, visit https://www.lacnets.org/podcast15. Play Video Play Video 20:24 Guided Meditation with Ruth - August 5, 2023 - LACNETS Virtual Wellness Retreat on Resilience Watch this guided meditation with Ruth. This session is part of the August 2023 LACNETS Virtual Wellness Retreat on Resilience. Play Video Play Video 20:29 Guided Meditation with Ruth - February 11, 2023 - LACNETS Virtual Wellness Retreat on Centeredness Watch this guided meditation with Ruth. This session is part of the LACNETS Virtual Wellness Retreat on Centeredness that took place on February 11, 2023. Play Video Play Video 32:11 Yoga with Julie • Feb 2023 • LACNETS Health & Wellness Retreat Health Coach Julie takes us through a gentle yoga session. For more information, visit LACNETS.org Play Video Play Video 32:38 Yoga with Julie - LACNETS 2022 Virtual Wellness Retreat Julie leads a yoga session as part of the 2022 LACNETS Virtual Wellness Retreat. Play Video Play Video 26:26 Meditation with Ruth - 2022 LACNETS Virtual Wellness Retreat Ruth leads a meditation session as part of the 2022 LACNETS Virtual Wellness Retreat. Play Video Play Video 28:09 Yoga as Gentle Mindful Movement for All Levels This is a 32-minute gentle yoga class geared specifically for those new to yoga or those who are interested in a gentle practice. Have a chair, mat and pillow handy. To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 20:31 Guided Meditation for Cultivating Intentions (20 minutes) This 20-minute guided meditation offers powerful techniques to reduce stress, cultivate intentions and find your inner calm. Meditation teacher: Ruth Q. Wolever, PhD, NBC-HWC Chief Science Officer, eMindful To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 33:05 Gentle Yoga for Body Awareness (for All Levels) This is a 30-minute gentle yoga class geared specifically for those new to yoga or those who are interested in a gentle practice. Have a chair, mat, wall space, and pillow handy. To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 19:13 Guided Meditation for Self-Healing This 19-minute meditation offers a powerful reset for your own self-healing. Meditation teacher: Ruth Q. Wolever, PhD, NBC-HWC Chief Science Officer, eMindful To learn more about LACNETS, visit www.LACNETS.org. Caregiving/Palliative/Supportive Care Caregiving/Palliative/Supportive Care Play Video Play Video 01:26:11 "Palliative Care for Neuroendocrine Cancer" Dr. Chandana Banerjee • 2024 #LACNETS Educational Event Learn about Palliative Care: what it is, what it is not, and how it may help those affected by neuroendocrine cancer. Dr. Chandana Banerjee, a palliative care and hospice specialist from the City of Hope Cancer Center in Los Angeles, demystifies these topics. Visit LACNETS.org for more information. Play Video Play Video 41:10 Episode 14: Palliative Care ABOUT THIS EPISODE What is palliative care and how does this relate to NET? Palliative care physician Dr. Chandana Banerjee of City of Hope shares insights and tips on communication, coping, and managing grief and loss. MEET DR. CHANDANA BANERJEE Chandana Banerjee, M.D., M.P.A., HMDC, is the Dean, Director and designated institutional official for Graduate Medical Education at City of Hope. She is also an assistant clinical professor in the Department of Supportive Care Medicine, specializing in hospice and palliative care. She developed the City of Hope Hospice & Palliative Medicine Fellowship. She also established the Cancer Pain Rotation for Kaiser Permanente Los Angeles Hospice & Palliative Medicine Fellowship, which is now part of the core curriculum for the Kaiser Permanente Southern California Hospice & Palliative Medicine fellowship program. Dr Banerjee also developed and directed the End of Life Symposium, which was first held at City of Hope in September 2019 and was endowed by Arthur Riggs, Ph.D. She is the physician lead for Schwartz Rounds at City of Hope and serves as chair on the End of Life Option Act Subcommittee. She is also a member of the Continuing Medical Education and the Ethics and Quality of Life committees. She co-founded the City of Hope Expressions of Hope initiative in partnership with Diversity, Equity and Inclusion. TOP 10 PALLIATIVE CARE QUESTIONS 1. What is palliative care? How is it different from hospice? 2. Who should be in palliative care? Who should not be in palliative care? 3. How does someone ask for palliative care? 4. Give an example of how palliative care can help someone living with NET. 5. What does coping with a cancer diagnosis look like? What suggestions do you have to help with coping? 6. What advice do you have for NET caregivers? 7. What insights or advice do you have to help with communication between NET patients and providers? NET patients and their loved ones? 8. What does end-of-life care planning look like? When should it begin? 9. What does the end of life look like for NET patients? 10. How can one manage grief and loss related to the cancer diagnosis? For more resources and a transcript of this episode, visit https://www.lacnets.org/podcast14. Play Video Play Video 16:29 13. Complementary Medicine (Dr. Duma) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Narjust Duma, MD Assistant Professor & Thoracic Oncologist UW Madison This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:02:18 LACNETS - "Pain Management for NETs" Dr. Najmeh Sadoughi Dr. Najmeh Sadoughi "Multidisciplinary Approaches to Pain Management for Neuroendocrine Tumors" Najmeh Sadoughi, MD Board Certified Interventional Pain Specialist LACNETS Patient Education Seminar January 9, 2018 UCLA Los Angeles, California LACNETS is a program by Generate Possibility, a 501(c)(3) non-profit corporation. Los Angeles Carcinoid Neuroendocrine Tumor Society www.LACNETS.org Play Video Play Video 05:40 16. Caregiver Story (Federico and Gilda) - 2021 LACNETS Virtual Conference NET caregiver Gilda shares her story about the importance of NET patient advocacy and support. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS This video is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:58 Patient Story: NET Patient shares her experience with the LACNETS health coaching program NET Patient Vivian shares her experience with the LACNETS health coaching program. August 28, 2020 To learn more about the LACNETS Health Coaching Program, visit www.LACNETS.org/healthcoaching. Play Video Play Video 01:37:15 LACNETS Webinar: Thriving with NETs - How Health & Wellness Coaching Can Help You LACNETS webinar - “Thriving with NETs - How Health & Wellness Coaching Can Help You" Friday, August 28th, 2020 SPEAKERS: Leeann Hays, RN, NBC-HWC Julie Oijala, RN, NBC-HWC Katherine Smith, NBC-HWC Ruth Q. Wolever, PhD, NBC-HWC Lisa Yen, NP, NBC-HWC Learn more here about the LACNETS Free Health Coaching Program: www.LACNETS.org/healthcoaching Audio/Video - www.TVPlive.com www.LACNETS.org Play Video Play Video 03:48 Caregiver Story: NET Caregiver shares about his experience as a caregiver to his wife (LACNETS) NET Caregiver Jack shares about his experience as a caregiver to his wife who is living with NET. November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 12:59 3. LACNETS 2020 Symposium - Living with Cancer & Covid, Patient Story LACNETS - 2020 Virtual NET Cancer Day Symposium Recorded on November 7th, 2020 Presentations: - LACNETS Intro (start - 1:21) - Patient Story (1:21 - 6:34) - "Living with Cancer & Covid" with Chandana Banerjee, MD, MPA, Assistant Clinical Professor Department of Supportive Care Medicine City of Hope (6:34 - end) To learn more about LACNETS, visit www.LACNETS.org. AV/Production by Rich Tamayo at TVPLive.com. Play Video Play Video 01:29:36 LACNETS Webinar - "What Matters Most? Meaningful Advance Care Planning as a Gift to Your Loved Ones" LACNETS webinar - "What Matters Most? Meaningful Advance Care Planning as a Gift to Your Loved Ones" Wednesday, May 6th, 2020 SPEAKER: Redwing Keyssar, RN Palliative Care Clinician, Author of "What Matters Most" Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com Play Video Play Video 01:42:18 LACNETS Webinar: "How to Ask For, Accept and Get the Help You Need" with Kim Hamer LACNETS Webinar: "How to Ask For, Accept and Get the Help You Need" with Kim Hamer Kim shares special insights on how to ask for and receive help, gained from losing her own husband to lung cancer. Speaker: Kim Hamer Author, 100 Acts of Love: A Girlfriend's Guide to Loving Your Friend through Cancer or Loss www.100actsoflove.com Learn more about LACNETS: www.LACNETS.org Audio/Video - www.TVPlive.com Music Heals Music Heals Play Video Play Video 13:54 "Circle Song" - Laugh and sing along with NET Patient Samuel Prentice Jr. Laugh and sing-along with NETCONNECT mentor Samuel Prentice Jr. He shares a song he wrote for the NET community titled "Circle Song." To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 04:17 "Hush" by Giovanna Joyce Imbesi (Photography by David F. Coppedge) [Written by David F. Coppedge] "Giovanna Imbesi, founder of LACNETS (Los Angeles County Neuroendocrine Tumor Society), died on November 24, 2019 after a 14-year battle with the disease. She worked tirelessly to educate and help patients with neuroendocrine cancer and support efforts to find new treatments. Giovanna was also an accomplished musician, pianist and composer. This is her song "Hush" from her album "Short Stories" that I put to some of my photographs of fall colors in Utah and Colorado. When I presented it to her in 2016, she was very appreciative, calling it "beautiful and touching." I offer it here on YouTube as a tribute to her hard work on behalf of others suffering from this rare cancer, and as a sample of her quiet spirit and desire for peace in the midst of years of surgeries and treatments for the life-threatening disease." < Back to Topics Next Topic >

Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC << Back Study of RYZ101 in Combination with SoC in Subjects with SSTR+ ES-SCLC IDENTIFIER ( ClinicalTrials.gov ) : NCT05595460 DRUG/TREATMENT : ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA) for injection + Carboplatin + Etoposide + Atezolizumab PHASE : 1b STATUS : Recruiting SPONSOR : RayzeBio, Inc. DESCRIPTION: Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC ." Recorded: June 20, 2024 RayzeBio is sponsoring this phase 1b trial with ALPHA PRRT with 225Ac-DOTATATE for extensive stage small cell lung cancer (ES-SCLC). This trial studies the safety and dosimetry to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 ( ALPHA PRRT with 225Ac-DOTATATE Actinium 225 radiolabeled somatostatin analog (SSA) in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : RayzeBio Clinical Trials EMAIL: clinicaltrials@rayzebio.com PHONE: 619-657-0302

Xermelo Resources https://www.xermelo.com/ Talk to a NET nurse about carcinoid syndrome diarrhea. Go to www.enrollxermelo.com . Download the TerSera Nursing Support Program brochure Download the Xermelo Patient Brochure

Research / Clinical Trials < Back to Topics Latest News on Clinical Trials Clinical Trials News Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Play Video Play Video 03:51 Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors Play Video Play Video 04:05 Dr. Soulen Talks About 2023 Highlights and His Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews Dr Michael Soulen, Interventional Radiologist at Penn. He talks about the highlights of 2023 and shares his hopes for 2024. Play Video Play Video 02:14 Dr. Kunz Shares 2023 Highlights and Her Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews NANETS Past President, Dr. Pamela Kunz. She talks about the highlights of 2023 and shares her hopes for 2024. Play Video Play Video 04:01 Dr. Strosberg Shares 2023 Highlights and Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews Dr. Jonathan Strosberg, Medical Oncologist at Moffitt. He talks about the highlights of 2023 and shares his hopes for 2024. Play Video Play Video 03:40 Dr. Halfdanarson Shares 2023 Highlights and His Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews NANETS President Dr. Thor Halfdanarson. He talks about the highlights of 2023 and shares his hopes for 2024. Play Video Play Video 03:52 Dr. Jennifer Chan Shares an Important Update about the CABINET Trial Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extra pancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future. Click here to read the detailed results of the CABINET trial announcement (https://www.businesswire.com/news/home/20231020586023/en/Detailed-Results-from-Phase-3-CABINET-Pivotal-Trial-Evaluating-Cabozantinib-in-Advanced-Neuroendocrine-Tumors-Presented-at-ESMO-2023?fbclid=IwAR18JTeSfpDVo9upMsyTrKssQfvT5vBrr0ifXJUaEKWDKh4nEcHQtRqC_M8) or the OncLive article here (https://www.onclive.com/view/cabozantinib-confers-pfs-benefit-in-previously-treated-advanced-neuroendocrine-tumors?fbclid=IwAR2bcn_e_CHS65aS5jQGaFvxG_NrE6mU-xnHfU6C33FH0DUL_i7g6yKrc10). Watch this exclusive video interview below with Dr. Jennifer Chan at ESMO - European Society for Medical Oncology 2023 in Madrid, Spain. Educational Videos on Research / Clinical Trials Educational Content on Research/Clinical... Play Video Play Video 28:41 Clinical Trials 101/Opportunities to Access NET Resources&Trials • Del Rivero MD • 2023 NETCancerDay Clinical Trials 101/Opportunities to Access NET Resources&Trials • Del Rivero MD • 2023 NET Cancer Day Symposium • Santa Monica, CA • @NCFCancer Speaker: Jaydira Del Rivero, MD Medical Oncologist Endrocrinologist National Cancer Institute, NIH For more information, visit LACNETS.org Play Video Play Video 16:37 "Understanding the Latest NET Clinical Trials" Dr. Pamela Kunz • 2024 #LACNETS Patient Conference 15) Understanding the Latest NET Clinical Trials • 2024 Neuroendocrine Tumor Patient Conference Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. Play Video Play Video 01:30:11 LACNETS • "Navigating Clinical Trials: Expectations vs. Realities" with Taymeyah Al-Toubah •Aug 2023 Join LACNETS to hear Taymeyah Al-Toubah, MPH, Senior Research Project Manager at the Neuroendocrine Tumor Program of Moffitt Cancer Center. About Our Speaker: Taymeyah Al-Toubah, MPH Senior Research Project Manager Neuroendocrine Tumor Program at Moffitt Cancer Center, Tampa, FL Taymeyah Al-Toubah is a clinical researcher, currently at Moffitt Cancer Center, who has been in the research field for 10 years. She began her career in 2013 while obtaining her bachelor’s degrees in biomedical sciences and psychology, working in pediatric and neonatal research at Johns Hopkins All Children’s Hospital. In 2016, she shifted her career focus to oncology, beginning with phase I trials and working in all solid tumors. She completed her Master of Public Health in Epidemiology in 2017 and focused her graduate thesis on neuroendocrine tumors. In 2018, she switched departments to focus exclusively on NETs. From 2018 – 2023, she was the primary NET coordinator in the GI department, managing all clinical trials while leading the GI team, managing the NET clinic coordination amongst the ancillary departments, and working on all retrospective and non-interventional NET research. She has worked on protocol development, database analysis, and manuscript writing, resulting in over 30 published manuscripts and presented her research at several national and international oncology and NET conferences, with oral abstracts at several ENETS and NANETS conferences. In April 2023, she formally transitioned to a new position as a project manager of the NET program, where she will continue to mentor new coordinators while working on protocol development and writing, manuscript writing, non-interventional clinical trials, and retrospective NET research. One of her first major projects will be to curate and develop a master database of all NET patients seen at her institution that will provide the basis for all future NET research to be published at Moffitt. She is currently on the board of one of the first NET patient advocacy groups in Florida (FLaNET Carcinoid Community), which kicked off alongside the Tampa Regional NANETS meeting in November 2022. She is an active member of NANETS on the Continuing Education and Symposium Planning committees. She plans to dedicate the remainder of her career to this disease and community. Her ultimate plan is to attend medical school, specialize in medical oncology, and continue to serve the academic NET community and patient base as a physician and clinical investigator. For more information, visit LACNETS.org. Play Video Play Video 17:07 Clinical Trials: Why, What & How • Josh Mailman • 2023 LACNETS Patient Education Conference Watch "Clinical Trials: Why, What & How" with Josh Mailman. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 18:39 The Latest in NET Clinical Trials • Dr. Simron Singh • 2023 LACNETS Patient Education Conference Watch "The Latest in NET Clinical Trials" with Dr. Simron Singh. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 01:34:45 LACNETS • "Novel Translational Research for Metastatic NET Patients at the NCI" • Jan 2023 Join LACNETS for this special educational event. What if you could both undergo surgery for your metastatic disease and also donate your liver tumor to find a cure for NET? Learn how you can contribute to NET research. The NET team at the National Cancer Institute (NCI) will give us a behind-the-scenes look at their innovative NET research. Be inspired by their hard work and dedication to the NET community. For more information, visit LACNETS.org. Play Video Play Video 01:32:12 LACNETS • "Update on NET Clinical Trials" with Dr. Heloisa Soares • Mar 2023 Join us for an "Update on NET Clinical Trials" with special guest Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah, to hear the latest in NET clinical trials. Visit LACNETS.org/Mar2023 for more information. Play Video Play Video 01:30:15 LACNETS Webinar: "2022: Year in Review" with Medical Oncologist Dr. Thor Halfdanarson Join LACNETS and medical oncologist Dr. Thorvardur Halfdanarson of Mayo Clinic for the webinar "2022: Year in Review" for an update on the major medical conferences of 2022. This webinar includes a presentation and Q&A. Speaker: Thor Halfdanarson, MD Medical Oncologist Mayo Clinic To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 01:27:49 LACNETS Webinar: "What's New with NETs?" with Pamela Kunz, MD of Yale Cancer Center What are the latest treatment options for neuroendocrine cancer? What's on the horizon for upcoming treatments and clinical trials? Dr. Pamela Kunz of Yale School of Medicine addresses these important topics and updates – plus answers your questions in a live Q&A. Speaker: Pamela Kunz, MD, Associate Professor of Medicine in the Department of Medicine Division of Oncology, Yale School of Medicine Director of the Center for Gastrointestinal Cancers, Yale Cancer Center To learn more about LACNETS, visit www.LACNETS.org. Load More In Depth Look at Active Clinical Trials In Depth Look: Active Clinical Trials Play Video Play Video 29:35 IL13Rα2 CAR T Cell Study for Solid Tumor Cancers • Dr. Anusha Kalbasi Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024. For more information about this trial, visit https://www.lacnets.org/clinical-trials-1/il13r%CE%B12-car-t-cell-study-for-solid-tumor-cancers. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 05:10 Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC • Dr. Aman Chauhan Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC. Recorded: June 20, 2024 Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 05:44 Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC • Dr. Aman Chauhan Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC. Recorded: June 20, 2024 Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 08:26 DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) • Dr. Aman Chauhan Boehringer Ingelheim is sponsoring a phase 1 study, a phase 1 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific or “BiTE”) that may help the immune system fight cancer. The study is in adults with extensive stage small cell lung cancer who have previously received platinum-based chemotherapy and are eligible to receive topotecan treatment. The purpose of this study is to find out the highest dose of BI 764532 that people can tolerate when taken together with topotecan, a chemotherapy treatment called topoisomerase 1 inhibitor, that works by blocking a chemical (topoisomerase 1) that helps cancer cells repair and separate DNA when they divide. Participants get BI 764532 and topotecan as infusions into a vein. As an alternative, topotecan may also be taken orally (tablets). Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 11:35 LACNETS • Lu177 Dotatate PRRT + M3814 (Peposertib) • Dr. Aman Chauhan Dr. Aman Chauhan discusses Lutetium Lu 177 dotatate in combination with M3814 (peposertib). IDENTIFIER (ClinicalTrials.gov): NCT04750954 Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 04:48 June 2024: Dr. Aman Chauhan Discusses the Alpha PRRT with Pb-212 VMT Study Dr. Aman Chauhan Discusses the Alpha PRRT with Pb-212 VMT Study. Recorded June 2024. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 08:42 June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study. Recorded in June 2024. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 13:45 April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study. Recorded in April 2023. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 08:01 Dr. Aman Chauhan discusses the DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON-5 is a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. This is a clinical trial for high grade neuroendocrine cancers. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. The study is sponsored by Boehringer Ingelheim. For more information, visit https://www.lacnets.org/clinical-trials-1/dareontm--5%3A-dll-3-bite-for-neuroendocrine-cancers. Load More Patient Stories: Clinical Trials Patient Stories: Clinical Trials Play Video Play Video 04:08 Patient Story: NET Patient shares about her experience in a clinical trial (LACNETS) NET Patient Mary shares about her experience in a clinical trial (Everolimus or Afinitor). November 7, 2020 To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 21:23 NET Clinical Trial: An Oral Somatostatin Analogue in Patients with Carcinoid Syndrome - Jan 2024 Crinetics is sponsoring a clinical trial to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment, an oral (pill) somatostatin analogue in patients with carcinoid syndrome. Learn more about the trial and inclusion criteria here. This trial is currently open at Hoag Cancer Center in Newport Beach, California with Dr. Michael Demeure. If interested, contact Clinical Research Nurse Coordinator Jericho Rabago via direct line 949-764-6796 or email Jericho.Rabago@hoag.org. Learn about more clinical trials here: lacnets.org/clinical-trials Play Video Play Video 07:10 Patient Story: NET Patient shares her experience with Alpha PRRT NET Patient DeAnne shares her experience with Alpha PRRT. March 16th, 2021 To learn more about the LACNETS , visit www.LACNETS.org. < Back to Topics Next Topic >